Mounjaro
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Mounjaro is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning · Medical Daily · 2026-09-29
- Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat · Latest Science News -- ScienceDaily · 2026-09-27
- Wegovy, Mounjaro help Korean doctor navigate lifelong struggle with obesity · Korea Times · 2026-09-22
- Young Koreans use digital placebos to curb spending · Korea Times · 2026-09-29
- Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come · 24/7 Wall St. · 2026-09-28
- McDonald’s is changing its menu for the Ozempic era · Fast Company · 2026-09-26
What the reporting says
Across 36 tracked stories from 21 outlets, reporting on Mounjaro most often describes public statements (2), award (2), acquisition (2), price levels (1), regulatory approvals (1), meetings or visits (1).
It shows up alongside GLP-1 (34), Eli Lilly (21), Zepbound (19), FDA (9), Nyse (9), Foundayo (8), Wall Street (8).
Two steps out: AI (through GLP-1, 34 shared stories on the weaker link); Amgen (through Eli Lilly, 21 shared stories on the weaker link); Astrazeneca (through Eli Lilly, 21 shared stories on the weaker link); China (through GLP-1, 21 shared stories on the weaker link).
Tracked since Sep 3, with coverage on 19 separate days — concentrated in Auto and South Korea.